Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. It is engaged in manufacturing, developing, and marketing a range of branded and generic formulations and active pharmaceutical ingredients (APIs). It produces a diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its global specialty portfolio spans advanced products in dermatology, ophthalmology, and onco-dermatology. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its vertically integrated operations deliver medicines to physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.
- Revenue in INR (TTM)492.09bn
- Net income in INR103.89bn
- Incorporated1993
- Employees43.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400 093IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | 297.18bn | 35.21bn | 893.94bn | 8.80k | 25.60 | -- | 17.57 | 3.01 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Mankind Pharma Ltd | 106.50bn | 19.63bn | 959.78bn | 19.54k | 48.98 | -- | 39.84 | 9.01 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | -- | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Lupin Ltd | 207.97bn | 22.64bn | 1.01tn | 20.79k | 44.94 | -- | 30.79 | 4.88 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 10,003,890.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.67 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 206.15bn | 41.69bn | 1.09tn | 26.24k | 26.16 | -- | 21.81 | 5.27 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 289.49bn | 55.65bn | 1.09tn | 26.34k | 19.68 | -- | 15.49 | 3.78 | 333.72 | 333.72 | 1,735.89 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Torrent Pharmaceuticals Ltd | 109.96bn | 17.35bn | 1.14tn | 14.92k | 65.53 | -- | 44.82 | 10.34 | 51.27 | 51.27 | 324.85 | -- | -- | -- | -- | 7,371,843.00 | -- | 8.34 | -- | 13.03 | 75.17 | 71.78 | 15.78 | 13.18 | -- | 8.19 | -- | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 261.39bn | 43.03bn | 1.33tn | 27.76k | 31.00 | -- | 24.73 | 5.10 | 53.27 | 53.27 | 323.59 | -- | -- | -- | -- | 9,414,760.00 | -- | 10.09 | -- | 12.40 | 66.43 | 58.63 | 16.58 | 12.66 | -- | 59.65 | -- | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 81.85bn | 16.74bn | 1.45tn | 17.50k | 86.74 | -- | 70.62 | 17.74 | 63.05 | 63.05 | 308.33 | -- | -- | -- | -- | 4,677,143.00 | -- | 16.55 | -- | 18.22 | 59.76 | 56.24 | 20.45 | 26.38 | -- | -- | -- | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Sun Pharmaceutical Industries Ltd | 492.09bn | 103.89bn | 4.41tn | 43.00k | 42.38 | -- | 33.71 | 8.95 | 43.32 | 43.32 | 205.18 | -- | -- | -- | -- | 11,443,900.00 | -- | 7.77 | -- | 10.85 | 78.50 | 71.59 | 21.35 | 14.23 | -- | 81.23 | -- | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 Aug 2024 | 87.76m | 3.66% |
| Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2023 | 72.27m | 3.01% |
| SBI Funds Management Ltd.as of 31 Aug 2024 | 49.70m | 2.07% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 40.98m | 1.71% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 25.57m | 1.07% |
| Norges Bank Investment Managementas of 31 Mar 2024 | 25.01m | 1.04% |
| GQG Partners LLCas of 30 Jun 2024 | 23.43m | 0.98% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Aug 2024 | 20.27m | 0.85% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Aug 2024 | 19.15m | 0.80% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 05 Sep 2024 | 18.82m | 0.78% |
